Teacher Retirement System of Texas Increases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Teacher Retirement System of Texas boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 37.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 236,140 shares of the medical research company's stock after purchasing an additional 63,911 shares during the period. Teacher Retirement System of Texas owned about 0.06% of Thermo Fisher Scientific worth $122,847,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TMO. Howard Capital Management Group LLC grew its holdings in shares of Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after purchasing an additional 286 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after buying an additional 225,568 shares during the last quarter. Prospera Financial Services Inc increased its holdings in shares of Thermo Fisher Scientific by 19.6% during the third quarter. Prospera Financial Services Inc now owns 4,549 shares of the medical research company's stock worth $2,816,000 after buying an additional 746 shares in the last quarter. Avior Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. Avior Wealth Management LLC now owns 3,956 shares of the medical research company's stock valued at $2,447,000 after acquiring an additional 30 shares in the last quarter. Finally, Prospera Private Wealth LLC increased its holdings in Thermo Fisher Scientific by 1,868.3% in the 3rd quarter. Prospera Private Wealth LLC now owns 9,940 shares of the medical research company's stock worth $6,149,000 after purchasing an additional 9,435 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Remove Ads

Thermo Fisher Scientific Stock Up 0.5 %

Shares of NYSE TMO traded up $2.53 during trading on Monday, hitting $520.25. 1,099,952 shares of the company traded hands, compared to its average volume of 1,538,823. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The business's fifty day moving average is $546.15 and its 200 day moving average is $555.52. The firm has a market capitalization of $196.27 billion, a price-to-earnings ratio of 31.47, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific's dividend payout ratio is presently 10.41%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 over the last three months. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research reports. UBS Group boosted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Wells Fargo & Company boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Finally, Citigroup reduced their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.